PneumRx, a medical device company, has received CE mark approval for its RePneu Lung Volume Reduction Coil (LVRC) system for commercialisation in Europe and other select markets, to treat the later stages of emphysema.
The RePneu LVRC System is a minimally invasive device intended to improve lung function in emphysema patients by brochoscopically implanting Nitinol coils into the lungs to compress damaged tissue and restore elastic recoil to the healthier lung tissue.
PneumRx president and CEO of Erin McGurk said that they are thrilled to have achieved this important milestone, and look forward to introduce RePneu LVRC to the European market to help improve the lives of emphysema patients and have few other viable treatment options.
“We are extremely pleased with the significant improvements in pulmonary function tests, exercise tolerance, and quality of life experienced by our clinical trial patients, and expect to bring these same benefits to a broader population of emphysema patients with the commercialisation of the RePneu LVRC System in Europe,” McGurk said.